Dihexa Benefits and Side Effects: Research Data

What Is Dihexa? A Small Molecule From Angiotensin IV

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, also coded PNB-0408) is built from two amino acids, tyrosine and isoleucine, with a hexanoyl cap on one end and a 6-aminohexanoic amide on the other. PubChem lists it as C₂₇H₄₄N₄O₅, molecular weight 504.7, CAS 1401708-83-5.^[8] It is usually sold among research peptides, but it is better described as a peptidomimetic small molecule.

It came out of Joseph Harding and John Wright’s angiotensin IV work at Washington State University. Angiotensin IV analogs had long been studied as procognitive agents, but they broke down quickly and could not cross the gut or the blood brain barrier. McCoy et al modified the active Nle-Tyr-Ile core to make it stable, and reported dihexa as orally active and able to cross into the central nervous system in rats.^[1] The authors declared that they founded and held shares in M3 Biotechnology, the company developing the technology.^[1]

The Proposed Mechanism: HGF/c-Met and Synapse Formation

The developers’ model is that dihexa binds hepatocyte growth factor and helps it pair up and activate c-Met, a growth factor receptor that supports neuronal survival, dendritic spine formation and synaptic plasticity. On that model, more HGF c-Met signalling means more synaptic connections and better cognitive function.^[9]

The evidence for that link is weaker than it looks. The HGF-binding and c-Met dependence data were in the 2014 paper that is now retracted, and the 2015 review that presented dihexa as an HGF/c-Met agent drew on that work.^[3][2][9] Some support comes from other research groups: in zebrafish hair cells, protection by dihexa was reduced by an HGF antagonist, and in a 2025 rat study a MET-blocking peptide cancelled dihexa’s effect on working memory.^[10][11] A stem-cell lab in Oslo also used dihexa as the HGF receptor agonist in a small-molecule method for turning human stem cells into liver-like cells.^[12]

Sources: developer mechanism and synapse data;^[3][1] independent MET-dependence, mouse and stem-cell findings.^[11][13][12]

Potential Dihexa Benefits Studied in Animal Models

Sources: developer memory study and its notice;^[1][4] independent mouse, brain injury and Huntington’s studies;^[13][11][14] hair-cell and nerve studies.^[10][15]

Cognitive impairment and Alzheimer’s disease models

The cognitive enhancement research on dihexa starts with McCoy et al. In rats, dihexa reversed scopolamine-induced memory deficits in the water maze and improved performance in aged rats, and it increased dendritic spine density in cultured hippocampal neurons.^[1] That paper is the basis of most claims about cognitive benefits, and it carries a 2021 Expression of Concern.^[4] In 2021 a group in Nanjing reported that dihexa restored spatial learning in APP/PS1 Alzheimer’s model mice, raised neuron counts and the synaptic marker synaptophysin, lowered the inflammatory cytokines IL-1β and TNF-α, and activated PI3K/AKT signalling; a PI3K inhibitor reversed the anti-inflammatory effect.^[13] This is animal data on cognitive decline models, not evidence of cognitive improvement in people.

Traumatic brain injury

A Rowan University team studied 52 male and female rats after repeated mild traumatic brain injury. Dihexa rescued working-memory deficits, and a MET antagonist peptide blocked most of that effect.^[11] The authors reported no competing financial interests. It is one study and has not been independently replicated.

Where the animal data disagree

In a randomised study of 40 rats exposed to a toxin that mimics Huntington’s disease, dihexa did not protect against weight loss, motor dysfunction or memory deficits.^[14] So across the three studies from outside the developer’s lab, two reported cognitive effects and one found none.

Dihexa and the Blood Brain Barrier: Oral Bioavailability and Half Life

Blood brain barrier penetration is a main selling point. McCoy et al designed dihexa to be more fat-soluble and less prone to hydrogen bonding, and described it as orally active and barrier permeant in rats.^[1] A developer-linked paper later described it as chemically stable and blood-brain barrier permeable, unlike native HGF.^[10] In the same 2013 paper, a small rat study (three to four animals per measurement) reported a long half life: about 12.7 days by one route and 8.8 days by another, with wide distribution into tissues.^[1] No human pharmacokinetic data exist, so oral bioavailability and half life in people are essentially unknown. The Alzheimer’s Drug Discovery Foundation listed the long half-life alongside its safety concerns.^[6]

The Potency Claim: Dihexa vs Brain Derived Neurotrophic Factor

Dihexa is often described as “seven orders of magnitude” or “10 million times” more potent than brain derived neurotrophic factor (BDNF). That potency claim comes from a 2012 Washington State University press release describing bench assays of new synapse formation in nerve cells.^[16] The peer-reviewed paper describing dihexa contains no such BDNF comparison, and no peer-reviewed head-to-head study was found.^[1] Potency comparisons drawn from press material are not supporting evidence for cognitive performance in people.

The Research-Integrity Record Behind the Dihexa Research

In 2021 the Journal of Pharmacology and Experimental Therapeutics placed an Expression of Concern on the 2013 McCoy et al paper.^[4] In 2025 it retracted the 2014 paper that proposed dihexa’s HGF/c-Met mechanism, after an investigation by Washington State University found falsified and/or fabricated data in its figures.^[2][3] PubMed lists 19 records that mention dihexa.^[17] The evidence base is small, and independent replication of the developer’s core findings has not been published.

Human Use: What Human Trials Exist?

None for dihexa specifically. A ClinicalTrials.gov search for dihexa returns no studies.^[5] The only clinical trials in this line tested fosgonimeton (ATH-1017), a separate phosphate prodrug developed by Athira Pharma, whose active metabolite works through the same HGF/MET system.^[18] In the LIFT-AD phase 2/3 trial (287 people with mild-to-moderate Alzheimer’s disease in the primary analysis, 26 weeks), fosgonimeton did not meet its primary or secondary endpoints. Serious adverse events were similar to placebo, but more participants stopped because of adverse events (14.2% vs 4.6%), mostly injection site reactions.^[19] These results show no clinical efficacy for the prodrug, and they cannot be read as data on dihexa itself.

Dihexa Side Effects: Is Dihexa Safe?

Nobody can say, because the safety data needed to answer that do not exist. What has been published:

• No human data. FDA has identified no human exposure data on drug products containing dihexa acetate, by any route, and lacks information on whether it would cause harm in humans.^[7]
• No long term safety studies. No study in animals or humans has examined the long-term safety of dihexa.^[6]
• A theoretical concern about cancer risk. MET is an oncogene: when genetically altered it can start and sustain cancer, and when activated it supports cancer cell survival, tumor growth and spread.^[20] Reviewers note that activating HGF and c-Met could, in theory, promote tumor growth and cancer progression. No study has tested this tumor biology question for dihexa.^[6]
• Persistence. The multi-day half life in rats means any effect, wanted or not, may last long after exposure.^[1][6]

Reports of side effects from informal human use are anecdotes, not safety data, so this article does not list them.

Dihexa Regulatory Status in 2026

Dihexa vs Semax: How Do the Two Cognitive Enhancement Compounds Compare?

The two are often named together, but they share almost nothing except the interest in cognitive disorders. Semax is a seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on the ACTH(4-10) fragment, with no hormonal activity, and it is a registered prescription medicine in Russia.^[23][24] In rats it bound specific sites in the basal forebrain and raised BDNF protein there.^[24] Its human data are small Russian studies; one in 110 patients after ischaemic stroke reported higher plasma BDNF and faster functional recovery on the Barthel index with Semax, a stroke recovery measure.^[25]

Sources: dihexa;^[1][5][21] Semax;^{[23][24][25][26]} both are listed under FDA’s “nominated but withdrawn” heading and neither is named by WADA.^[7][22] On the evidence base, Semax has more human data, though it is small and mostly from its developers’ country. No study has compared the two or tested combining dihexa with Semax. For the full picture see Semax benefits and side effects and the Semax research review.

What the Research Does Not Yet Show

• A confirmed mechanism. The HGF-binding evidence was retracted, and it has not been independently replicated.^[3]
• Consistent animal results. Independent studies conflict.^[13][11][14]
• Toxicology and cancer testing. Neither has been done.^[6]
• Any human data. There are no human clinical trials of dihexa, and the prodrug trial did not show clinical efficacy.^[5][19]

The clinical implications of the dihexa literature are therefore limited. It remains a tool for experimental therapeutics research on HGF/MET signalling, read alongside its integrity record.

Dihexa for Laboratory Research

Remy Research supplies dihexa for in-vitro laboratory research as the Genovare Dihexa 25mg AQ pen. The product page carries its batch testing details. For the full evidence review, read the dihexa research review; for related neuroscience compounds, see the Cerebrolysin review and Semax vs Selank.